Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by BearDownAZon Feb 25, 2017 2:25pm

180 Views

Post# 25893650

RE:microbiome

Resverlogix first presented on a microbiome-related theme back in September 2016 at the EASD meeting. Here's the RVX blog on the presentation that also has a link to an eVideo for Dr. Wong's EASD 2016 presentation. I'm sure there will be some new data related to this apabetalone/microbiome/complement relationship in the March 2017 ACC presentation, but the full abstract is embargoed until March 6th. So we wait and see.

Bullboard Posts

Paramount Resources signs $3.32 billion asset sale